The harmonised PIC/S-EMA-WHO interpretation of the most important changes in Annex 1 on the manufacture of sterile products (2022) has now been published. In this blog post, Graham Carroll (Lead Senior GMDP Inspector and PIC/S Annex 1 Implementation Working Group member) highlights what this means for pharmaceutical manufacturers.
The 2022 revision of Annex 1 represented a significant development in GMP expectations for the manufacture of sterile medicinal products. Since its publication, industry and regulators have been applying those requirements across a wide range of facilities, technologies, and manufacturing processes.
Following the introduction of the Annex 1 revision, a Joint Implementation Working Group was established, bringing together members from the Pharmaceutical Inspection Co-operation Scheme (PIC/S), European Medicines Agency (EMA) and World Health Organization (WHO). One of its objectives was to support a harmonised interpretation of the revised Annex 1. PIC/S has now published PI 058-1: Interpretation of the most important changes in the Annex 1 on the manufacture of sterile products (2022). The document entered into force on 28 October 2026 and brings together answers to important questions arising from the revision and implementation of Annex 1.
As a member of the working group, I am proud to have contributed to its development and to see the results of that considerable collective effort now published. This is a clear example of how the MHRA collaborates with trusted partners to actively shape global regulatory practice.

Why is the document important for pharmaceutical manufacturers?
Although the document has been developed to support a harmonised inspection approach, the working group was also keen that the interpretations should be accessible to industry. Inspections are an important part of protecting patient safety, but manufacturers should not have to wait until their next inspection to understand how aspects of Annex 1 are being interpreted. By publishing the document, manufacturers can consider those interpretations proactively and review their approach where appropriate, rather than first encountering an issue during an inspection.
PIC/S is clear that the purpose of PI 058-1 is not to introduce any new GMP requirements, nor does the document override the requirements of Annex 1, which remains the underlying requirement. The Q&A supports a harmonised approach to inspection by providing interpretations of some of the most important changes introduced in the 2022 revision. The document does not attempt to address every change made to Annex 1, but focuses on key questions arising during the revision process and following implementation.
The value of the Q&A is not as another checklist to place alongside Annex 1. Instead, it provides an opportunity for manufacturers to consider how they have interpreted and implemented Annex 1 and to compare their reasoning with the interpretations developed through the joint international working group.
Look beyond the individual answers
I am deliberately not going to summarise each of the questions and answers here. I would strongly encourage manufacturers to read the PIC/S publication itself.
The questions cover a broad range of practical issues across sterile manufacture, including the Contamination Control Strategy (CCS), facilities and cleanrooms, barrier technologies, personnel qualification, sterilisation, aseptic processing and interventions, sterilising filtration, single-use systems, environmental monitoring, and microbiological control.
There is considerable technical detail behind some of the answers, and reading them alongside the corresponding paragraphs of Annex 1 is more useful than looking at individual statements in isolation.
One theme that comes through strongly is the relationship between Quality Risk Management (QRM), scientific knowledge, and the CCS. Annex 1 provides scope for risk-based approaches in several areas, but the answers repeatedly illustrate the importance of understanding the underlying risk and having appropriate scientific or technical justification. The detail and use of the CCS similarly runs through many of the answers rather than appearing as a standalone exercise.

Using the Q&A in practice
For manufacturers, I would suggest reading PI 058-1 with your own operation in mind rather than simply reviewing it as a regulatory update. Where a question is relevant to your processes, consider the corresponding Annex 1 requirement and whether the interpretation should prompt you to revisit your current approach, its rationale or the evidence supporting it.
That does not mean that every example in the Q&A becomes an additional GMP requirement, nor that doing something differently automatically represents a deficiency. It does, however, provide a useful opportunity to challenge established assumptions within your organisation.
That could include looking again at how QRM has been applied, whether the CCS reflects current process knowledge and monitoring data, whether qualification and validation evidence supports the controls being relied upon, and whether the rationale behind important contamination-control decisions can be clearly explained.
Those are useful questions for any manufacturer to ask itself, independently of an inspection.
Not the end of the story
Despite the considerable work that has gone into this document, there will inevitably be areas that prompt further questions or where future interpretation may be helpful. This is version 1 of the document, and feedback from inspectors and industry will provide valuable input when future revisions are considered.
Inspections are not intended to be the forum for detailed feedback on the document itself. Industry feedback should instead be provided through the appropriate regulatory channels. For UK stakeholders, feedback can be submitted to the PIC/S Secretariat at info@picscheme.org, with the subject “Annex 1 Interpretation document”. It is particularly helpful if feedback identifies the relevant paragraph or question, clearly describes the issue, and provides a technically supported proposal or rationale.

A considerable collective effort
The relatively short final document inevitably hides the scale of the work behind it. It is no exaggeration to say that thousands of hours of discussion, drafting, review and technical consideration went into reaching the final document. That considerable collective effort reflected a shared objective; to provide useful interpretations that support greater consistency in how the revised Annex 1 is understood and applied.
I hope manufacturers will also benefit from the extensive work that went into this document. It is a relatively concise read, but one that should prompt some worthwhile conversations about how Annex 1 has been implemented in practice. I would encourage manufacturers to read the Q&A in full, consider the questions relevant to their operations and use them as an opportunity to reflect on their own implementation of Annex 1.
Leave a comment